Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated.

Trial Profile

Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2015

At a glance

  • Drugs Sorafenib (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SOFIA
  • Most Recent Events

    • 02 May 2012 Actual patient number (36) added as reported by ClinicalTrials.gov.
    • 02 May 2012 Actual end date (December 2011) added as reported by ClinicalTrials.gov.
    • 02 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top